New South Wales

Poisons and Therapeutic Goods Amendment (Prescriptions) Regulation 2020

under the

Poisons and Therapeutic Goods Act 1966

Her Excellency the Governor, with the advice of the Executive Council, has made the following Regulation under the *Poisons and Therapeutic Goods Act 1966*.

BRAD HAZZARD, MP
Minister for Health and Medical Research

Explanatory note

The objects of this Regulation are—

(a) to provide for prescriptions for restricted substances issued by medical practitioners and nurse practitioners to be sent to pharmacists by email or facsimile for 12 months because of the COVID-19 pandemic, and

(b) to include new prescribed restricted substances, and

(c) to exempt hospitals from current storage requirements for those new substances for 12 months.

This Regulation is made under the *Poisons and Therapeutic Goods Act 1966*, including sections 16, 17, 18A(1) and 45C (the general regulation-making power).

Published LW 17 April 2020 (2020 No 153)

Poisons and Therapeutic Goods Amendment (Prescriptions) Regulation 2020

under the

Poisons and Therapeutic Goods Act 1966

1 Name of Regulation

This Regulation is the *Poisons and Therapeutic Goods Amendment (Prescriptions) Regulation 2020*.

2 Commencement

This Regulation commences on the day on which it is published on the NSW legislation website.

Schedule 1 Amendment of Poisons and Therapeutic Goods Regulation 2008

[1] Clause 30 Storage of prescribed restricted substances in hospital wards

Insert after clause 30(2)—

(3) This clause does not apply to the storage of the prescribed restricted substances inserted into Appendix D by the *Poisons and Therapeutic Goods Amendment (Prescriptions) Regulation 2020* until 5 April 2021.

[2] Clause 36A

Insert after clause 36—

36A Special provisions for prescribing restricted substances during COVID-19 pandemic

(1) During the prescribed period, a medical practitioner or nurse practitioner may issue a prescription for a restricted substance by sending a prescription to a pharmacist by email or facsimile.

(2) A medical practitioner or nurse practitioner who issues a prescription for a restricted substance in accordance with this clause must keep the prescription.

(3) A pharmacist to whom a prescription is sent under this clause must—

(a) print a copy of the prescription, and

(b) keep a printed copy.

(4) The copy of the prescription printed by the pharmacist is taken to be a prescription for the purposes of Division 4 of this Part.

(5) This clause does not apply to a medication chart prescription.

(6) In this clause—

prescribed period means the period commencing on the commencement of this clause and ending on 4 April 2021.

restricted substance does not include a prescribed restricted substance or a special restricted substance.

[3] Appendix D Prescribed restricted substances

Insert in alphabetical order—

AOD-9604 (CAS No. 221231-10-3)	0.10 gram
CJC-1295 (CAS No. 863288-34-0)	0.50 gram
Fibroblast Growth Factors	0.10 gram
Growth Hormone Releasing Hormones (GHRHs) including those separately specified in Schedule 4 of the Poisons List	0.50 gram
Growth Hormone Releasing Peptide-6 (GHRP-6)	0.50 gram
Growth Hormone Releasing Peptides (GHRPs) including those separately specified in Schedule 4 of the Poisons List	0.50 gram
Growth Hormone Secretagogues including those separately specified in Schedule 4 of the Poisons List	0.50 gram
Hexarelin	0.50 gram
Ibutamoren	0.50 gram

Ipamorelin	0.50 gram
Perampanel for human use	0.80 gram
Pralmorelin ((Growth Hormone Releasing Peptide-2) (GHRP-2))	0.50 gram
Pregabalin	30.0 grams
Quetiapine	40.0 grams
Stenabolic (SR9009) and other synthetic REV-ERB agonists	2.0 grams
TB-500	0.30 gram
Thymosin Beta 4 (THYMOSIN ß4)	0.30 gram
Tianeptine	3.75 grams
Tramadol	30.0 grams
Zolpidem	1.0 gram
Zopiclone	0.75 gram